Purpose: In this work, we tested the hypothesis that microneedles provide a minimally invasive method to inject particles into the suprachoroidal space for drug delivery to the back of the eye.
Methods: A single, hollow microneedle was inserted into the sclera, and infused nanoparticle and microparticle suspensions into the suprachoroidal space. Experiments were performed on whole rabbit, pig, and human eyes ex vivo. Particle delivery was imaged using brightfield and fluorescence microscopy as well as microcomputed tomography.
Results: Microneedles were shown to deliver sulforhodamine B as well as nanoparticle and microparticle suspensions into the suprachoroidal space of rabbit, pig, and human eyes. Volumes up to 35 μL were administered consistently. Optimization of the delivery device parameters showed that microneedle length, pressure, and particle size played an important role in determining successful delivery into the suprachoroidal space. Needle lengths of 800-1,000 μm and applied pressures of 250-300 kPa provided most reliable delivery.
Conclusions: Microneedles were shown for the first time to deliver nanoparticle and microparticle suspensions into the suprachoroidal space of rabbit, pig and human eyes. This shows that microneedles may provide a minimally invasive method for controlled drug delivery to the back of the eye.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038673 | PMC |
| http://dx.doi.org/10.1007/s11095-010-0271-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Meta-Analysis of MINIject vs. Two iStents as Standalone Treatment for Glaucoma with 24 Months of Follow-Up.
J Clin Med
December 2024
Swiss Visio Glaucoma Research Center, Montchoisi Clinic, 1006 Lausanne, Switzerland.
This study compares the long-term intraocular pressure (IOP)-lowering efficacy of standalone MINIject (iSTAR Medical, Belgium) suprachoroidal implantation and two iStent (Glaukos, CA, USA) trabecular bypass implantation using a systematic review and meta-analysis. Systematic review of standalone implantation of MINIject or iStent inject with at least 24 months of follow up. The mean and standard deviation of IOP and the number of IOP-lowering medications at baseline and at 24 months were extracted.
View Article and Find Full Text PDFDevelopment of self-healing hydrogels to support choroidal endothelial cell transplantation for the treatment of early age related macular degeneration.
Acta Biomater
December 2024
Institute for Vision Research, Carver College of Medicine; University of Iowa, Iowa City, IA; Department of Ophthalmology and Visual Sciences, Carver College of Medicine University of Iowa, Iowa City, IA. Electronic address:
In retinal diseases such as age-related macular degeneration (AMD) and choroideremia, a key pathophysiologic step is loss of endothelial cells of the choriocapillaris. Repopulation of choroidal vasculature early in the disease process may halt disease progression. Prior studies have shown that injection of donor cells in suspension results in significant cellular efflux and poor cell survival.
View Article and Find Full Text PDFOptical clearing with tartrazine enables deep transscleral imaging with optical coherence tomography.
J Biomed Opt
December 2024
Duke University Medical Center, Department of Ophthalmology, Durham, North Carolina, United States.
Significance: Imaging deep structures with optical coherence tomography (OCT) is difficult in highly scattering biological tissue, such as the sclera. There is a need to visualize the suprachoroidal space and choroid through the sclera to study suprachoroidal drug delivery.
Aim: We aim to develop optical methods to image through the highly scattering sclera with a custom-built OCT system to visualize the suprachoroidal space and drug delivery within.
In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment.
JAMA Ophthalmol
December 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Importance: In-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety.
Objective: To report outcomes with in-office SCVEXY for primary acute RRD.
Design, Setting, And Participants: This retrospective case series was conducted at St Michael's Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina.
Suprachoroidal drug delivery: a versatile therapeutic platform.
Expert Opin Drug Deliv
December 2024
Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!